inhibition of the renin-angiotensin system (ACEI or ARB)

     

pathologytreatmentpatient Demonstrated benefit and harm k      
heart failurecandesartannot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
heart failureirbesartannot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
heart failureperindoprilnot classified

versus placebo or no treatment

No demonstrated result for efficacy

perindopril inferior to placebo in terms of Hospitalisation in PEP CHF, 2006

1 trialmeta-analysis
patients at high risk for cardiovascular eventsenalaprilnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
patients at high risk for cardiovascular eventsperindoprilnot classified

versus placebo or control

No demonstrated result for efficacy

perindopril inferior to placebo in terms of Toux in EUROPA, 2003

perindopril inferior to placebo in terms of hypotension in EUROPA, 2003

perindopril inferior to placebo in terms of Arrêt pour effet secondaire in EUROPA, 2003

1 trialmeta-analysis
patients at high risk for cardiovascular eventsquinaprilnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
patients at high risk for cardiovascular eventsramiprilnot classified

versus placebo or control

No demonstrated result for efficacy

ramipril inferior to placebo in terms of Toux in HOPE, 2000

ramipril inferior to placebo in terms of Angiodème in HOPE, 2000

1 trialmeta-analysis
patients at high risk for cardiovascular eventsramiprilnot classified

versus

No demonstrated result for efficacy

telmisartan + ramipril inferior to ramipril in terms of Insuffisance rénale in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of hypotension in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to ramipril in terms of Arrêt pour effet secondaire in ONTARGET (association vs ramipril), 2008

telmisartan + ramipril inferior to telmisartan in terms of Insuffisance rénale in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Toux in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of hypotension in ONTARGET (association vs telmisartan), 2008

telmisartan + ramipril inferior to telmisartan in terms of Arrêt pour effet secondaire in ONTARGET (association vs telmisartan), 2008

2 trialsmeta-analysis
patients at high risk for cardiovascular eventstelmisartannot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
patients at high risk for cardiovascular eventstelmisartannot classified

versus

No demonstrated result for efficacy

telmisartan inferior to ramipril in terms of hypotension in ONTARGET (telmisartan alone), 2008

1 trialmeta-analysis
patients at high risk for cardiovascular eventstrandolaprilnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis